Estimating Changes in Medicare Part D and Commercial Insurer Insulin Spending Amid Planned State-Led Biosimilar Insulin Production in California

Author:

Anderson Kelly E.1,Xuan Andrew2,Anderson Gerard F.2,Socal Mariana P.2

Affiliation:

1. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora

2. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Abstract

This cross-sectional study evaluates the cost savings of state-led manufacturing and selling of biosimilar insulin.

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Reference6 articles.

1. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018.;Hernandez;JAMA,2020

2. Cost-related insulin underuse among patients with diabetes.;Herkert;JAMA Intern Med,2019

3. When states step up: California and the case for state-led insulin manufacturing.;Socal;Ann Intern Med,2022

4. State of California. Budget change proposal 4140-079-BCP-2022-A1: reducing the cost of insulin—CalRx Biosimilar Insulin Initiative. Department of Health Care Access and Information. Accessed July 31, 2022. https://esd.dof.ca.gov/Documents/bcp/2223/FY2223_ORG4140_BCP5779.pdf?

5. SSR Health website. Accessed June 1, 2022. https://www.ssrhealth.com/us-brand-rx-net-price-tool/

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3